Philips to acquire Intact Vascular

Image source: Philips

News • Expanding image-guided therapy devices portfolio

Philips to acquire Intact Vascular

Royal Philips announced that it has signed an agreement to acquire Intact Vascular, Inc., a U.S.-based developer of medical devices for minimally-invasive peripheral vascular procedures.

Intact Vascular will enhance Philips’ image-guided therapy portfolio, combining Philips’ interventional imaging platform and diagnostic and therapeutic devices with Intact Vascular’s unique, specialized implantable device to optimize the treatment of patients with Peripheral Artery Disease (PAD). PAD develops when plaque builds up in arteries and reduces blood flow to the limbs, most commonly the legs. It affects more than 200 million people worldwide. PAD symptoms include recurrent fatigue, leg pain, and foot or leg wounds that do not heal or heal very slowly. Critical Limb Ischemia (CLI) is an advanced stage of PAD, and is typically associated with high rates of amputation and mortality.

Photo
The Tack Endovascular System, an implant for treatment of Peripheral Artery Disease (PAD)

Image source: Philips

“Acquiring Intact Vascular will expand our portfolio of minimally invasive therapy options for Peripheral Artery Disease with the Tack Endovascular System, a much needed implant that effectively restores blood flow in small limb vessels, promotes healing and preserves limbs,” said Chris Landon, Senior Vice President and General Manager Image Guided Therapy Devices at Philips. “Through the integration of our interventional imaging systems and diagnostic and therapeutic devices, we will be able to provide clinicians with a complete procedural solution to optimize the treatment of patients with this disease.”

Philips’ peripheral vascular portfolio already includes advanced interventional imaging systems for precision guidance; intravascular ultrasound (IVUS) catheters to assess the location of the disease and lesion morphology and guide and confirm the treatment; peripheral atherectomy devices to remove blockages; and peripheral therapy devices, such as Philips’ Stellarex drug-coated balloon, to treat lesions.

We share the same vision of complete procedural solutions to improve existing procedures and expand treatment option

Bruce Shook

Intact Vascular will strengthen this portfolio with the Tack Endovascular System, which reinforces standard and drug-coated balloon PAD treatment results. Intact Vascular’s Tack implant is a first-of-its-kind, minimal-metal, dissection repair device that provides precision treatment of peripheral arterial dissections following balloon angioplasty in above-the-knee (ATK) and below-the-knee (BTK) therapeutic interventions. The Tack implant leaves less metal behind compared to stents, preserving future treatment options and ultimately preserving limbs. Moreover, Intact Vascular’s Tack implant offers a solution for repairing dissections and optimizing post-angioplasty outcomes in the challenging CLI patient population. “We are excited about the strategic fit between our team, expertise and unique therapeutic device, and Philips’ Image-Guided Therapy business,” said Bruce Shook, President and CEO of Intact Vascular. “We share the same vision of complete procedural solutions to improve existing procedures and expand treatment options. We look forward to completing the transaction and working closely with Philips on a seamless transition.”

The transaction, which is subject to customary closing conditions, is expected to be completed in the third quarter of 2020. Philips will acquire Intact Vascular for an upfront cash consideration of $ 275 million (approx.  € 234 million), and deferred payments for which the company expects to recognize a provision of USD 85 million (approx. € 72 million) upon completion of the transaction.


Source: Philips

28.08.2020

Read all latest stories

Related articles

Photo

Article • Oncology imaging

The expanding role of CT in lung cancer management

While screening programs for several of the commonest cancers are now well established, lung cancer screening has yet to reach anywhere near the same proportion of at-risk patients.

Photo

Article • Philips presents portfolio update at ECR 2022

AI-powered MRI to increase imaging speed, reduce staff burden

The portfolio Philips presented at ECR 2022 revealed that the company not only advanced their products, but also listened to medical professionals and patients – and took their feedback to heart.

Photo

Sponsored • Radiology collaboration

Improved workflow and a touch of Disney magic

Improving workflow is one of the major challenges that radiology departments face. The need to be more efficient, deliver timely and effective patient care, and keep an eye on costs are all factors…

Related products

Subscribe to Newsletter